UCB
Pharma companywww.ucb.com
62
MENTIONS
20
EPISODES
13
PODCASTS
Search complete. 62 mentions across 20 episodes found for "UCB".
Sep 16, 2026
Otis JohnsonHOST
Welcome to the September sixteenth edition of the Applied Clinical Trials Brief.
Otis JohnsonHOST
In part four of her interview, Emily Lowth of UCB Pharma shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency about what makes trial participation possible and what makes it not.
Otis JohnsonHOST
Feasibility is not determined by disease severity alone, but by whether the trial's visit burden, travel requirements, and measurement regimens align with how families actually live and manage their conditions.
Otis JohnsonHOST
In a new contributed article, Partha and Jayanth Ianville examined how preclinical CRO partnerships have evolved from transactional vendor relationships to strategic alliances where CROs contribute intellectual property, innovate, and create value alongside sponsors.
Otis JohnsonHOST
Welcome to the September 15th edition of the Applied Clinical Trials Brief.
Otis JohnsonHOST
In part three of her interview, Emily Loth of UCB Pharma describes how shifting patient engagement from protocol review to endpoint selection transforms both the quality of trial data and the experience of participation.
Otis JohnsonHOST
When patients shape which outcomes matter, trials measure what actually matters to the people they serve and generate more clinically meaningful results.
Otis JohnsonHOST
In a new FAQ article, we addressed why clinical trial infrastructure has to be built before AI can deliver, examining the execution gaps in decision workflows, data collection design, and lab connectivity that remain fragmented.
Otis JohnsonHOST
Welcome to the September fourteenth edition of the Applied Clinical Trials Brief.
Otis JohnsonHOST
In part two of her interview, Emily Lowth, Global Medical Community Head for Rare Epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms.
Otis JohnsonHOST
Outcomes families actually hope for include developmental milestones, quality of life, and reduced caregiver burden, not just seizure reduction.
Otis JohnsonHOST
Endpoints must include what families want to see change, not what's easiest to measure.
Otis JohnsonHOST
Welcome to the September 11th edition of the Applied Clinical Trials Brief.
Otis JohnsonHOST
In part one of a new interview, Emily Loth, Global Medical Community Head for Rare Epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written.
Otis JohnsonHOST
When patients and caregivers say a trial was designed with them in mind, that alignment reflects input that shaped core decisions, not consultative feedback added after structure was locked.
Otis JohnsonHOST
In a new Q&A article, John Warden, Chief Commercial Officer at Javara, discussed why AI-enabled recruitment must combine patient identification at scale with the clinician relationships that build trust.
Maya PatelHOST
The White House added nine more manufacturers to its most favored nation pricing agreements on Monday.
Maya PatelHOST
Alcon, Astellas, B1, Bridge Bio, CSL, Keogh-Wukiran, Sun Pharma, Teva, and UCB.
Maya PatelHOST
That takes the program to 26 companies and, by the administration's count, 89% of the branded market.
Maya PatelHOST
What the nine committed to is Medicaid access at MFN prices and MFN pricing on new launches, plus a collective pledge of at least $19.6 billion in U.S. manufacturing.
Jeff AxtHOST
In total, according to the White House, MFN deals now cover some 89% of the branded drug market.
Annalee ArmstrongHOST
Yeah, so among the companies that have now signed on to this include Astellas Pharma, B1 Medicines, UCB, and Teva.
Annalee ArmstrongHOST
The companies have collectively committed nearly $20 billion in manufacturing investments in the U.S., the White House announced at the same time.
Annalee ArmstrongHOST
So that brings the full coverage of MFN to about 89% of branded drugs in the U.S. Analysts have said that the agreements were a positive move for these companies and could shield them from some tariff concerns, some other initiatives of the White House.
Donald TrumpSOUNDBITE_SPEAKER
They're largely standing behind me.
Donald TrumpSOUNDBITE_SPEAKER
I want to thank The president of Astellas Pharma Medical, Michael Putratis, and CEO of B1 Medicines, John Euler, CEO of Bridge Bio, Neil Kumar, Senior Vice President of CSL, Julie Schiffman, CEO of Sun Pharma, Rick Ashcroft, President of Keio Kirin, Steve Schaefer, Executive Vice President of Teva Pharmaceuticals USA, Christine Fox, CEO of UCB, Dr. Jean-Christophe Tellier.
Donald TrumpSOUNDBITE_SPEAKER
I think I got those names almost right.
Donald TrumpSOUNDBITE_SPEAKER
That's a group of very interesting names.
8 MINS LATER
Donald TrumpSOUNDBITE_SPEAKER
And right now, There are more people working in the United States than ever before.
Donald TrumpSOUNDBITE_SPEAKER
We have never had as many people working as we have today, which I think is a great stat.
Donald TrumpSOUNDBITE_SPEAKER
I especially want to thank UCB, Sun, Pharma, Teva, and Estelas.
Donald TrumpSOUNDBITE_SPEAKER
for contributing a combined 290 metric tons of active pharmaceutical ingredients to our strategic reserve.
Mike ChristelHOST
GSK pushes its dual antigen mRNA flu vaccine, FLUM, 3HA.B-3NA into a first-of-its-kind Phase III trial, and Simseer Zymine Licenses, its tri-specific antibody, Sim-0660-Taroche, in a deal worth up to $1.53 billion.
Mike ChristelHOST
The Trump administration adds nine mid-sized drug makers, including Teva Pharmaceuticals, CSL, and UCB, to its Most Favored Nation pricing program.
Mike ChristelHOST
requiring the companies to price their medications at the lowest rate offered in other developed nations across all U.S. Medicaid programs.
Mike ChristelHOST
The nine collectively committed to investing at least $19.6 billion in U.S. manufacturing and contributing active pharmaceutical ingredients, including UCB's stockpile of the anticonvulsant levotiracetam to a new strategic active pharmaceutical ingredients reserve.
Mike ChristelHOST
The deals bring the MFN program to 26 manufacturers, covering roughly 89% of the branded drug market, completing agreements with all 17 companies the administration originally targeted in July 2025.
Mike ChristelHOST
GSK advances its dual-antigen mRNA seasonal influenza vaccine into a Phase III efficacy trial beginning in September.
Donald TrumpSOUNDBITE_SPEAKER
President of Keogh Kiran, Steve Schaffer.
Donald TrumpSOUNDBITE_SPEAKER
Executive Vice President of Teva Pharmaceuticals USA, Christine Fox, CEO of UCB, Dr. Jean-Christophe Tellier.
Donald TrumpSOUNDBITE_SPEAKER
I think I got those names almost right.
Donald TrumpSOUNDBITE_SPEAKER
That's a group of very interesting names.
8 MINS LATER
Donald TrumpSOUNDBITE_SPEAKER
There are more people working in the United States than ever before.
Donald TrumpSOUNDBITE_SPEAKER
We have never had as many people working as we have today, which I think is a great stat.
Donald TrumpSOUNDBITE_SPEAKER
I especially want to thank UCB, Sun, Pharma, Teva, and Estelas for contributing a combined 290 metric tons of active pharmaceutical ingredients to our strategic reserve.
Donald TrumpSOUNDBITE_SPEAKER
We have a strategic reserve.
10 more episodes mention UCB.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.